Nanog Predicts Poor Prognosis in Human Pancreatic Cancer and Is Downregulated by QingyihuaJi Formula in Pancreatic Cancer Stem Cells

Song Gao,1,2 Yan Pan,1,2 Libin Song,1,2 Lei Dong,2,3 Lao I. Weng,2,3 Peng Wang,1,2 Yongqiang Hua,1,2 Zhen Chen,1,2 and Luming Liu1,2

1Department of Integrative Oncology, Fudan University Shanghai Cancer Center, Shanghai 200032, China
2Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China
3Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai 200032, China

Correspondence should be addressed to Luming Liu; liulml010@163.com

Received 18 April 2016; Revised 7 August 2016; Accepted 11 August 2016

Academic Editor: Francesca Borrelli

Copyright © 2016 Song Gao et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Qingyihuaji formula (QYHJ), confirmed efficacious in a series of clinical trials, has been applied to human pancreatic carcinoma treatment in Shanghai Cancer Center for years. Recent evidence highlighted that pluripotent stem cells transcription factor Nanog plays a pivotal role in carcinogenesis. However, there is little published information regarding the underlying clinical significance and mechanisms of transcription factor Nanog in pancreatic cancer. In this study, our results indicated that Nanog is overexpressed in human pancreatic cancer stem cells and downregulated by QYHJ, which may contribute to explain the clinical effectiveness of QYHJ and provide advanced pancreatic cancer patients with a new therapeutic option, supporting our hypothesis that the degradation pathway is another mechanism by which QYHJ affects Nanog expression.

1. Introduction

Pancreatic cancer is a devastating neoplasm and ranks the fourth among the most common causes of cancer deaths worldwide [1]. Although great advances have been made in the treatment of pancreatic cancer, the conventional therapies, such as surgery, radiotherapy, and chemotherapy, are limited and the prognosis is dismal [2, 3]. Therefore, the median overall survival is only 5-6 months after conventional therapies for locally advanced and metastatic disease. Consequently, the five-year survival rate of PDAC is merely 6% [4]. Thus, a better understanding of the genetic alterations and detailed molecular mechanisms involved in pancreatic cancer development will facilitate advances in the prevention, diagnosis, and treatment of this lethal disease.

Qingyihuaji formula (QYHJ), composed of traditional Chinese herbs, has been applied to human pancreatic cancer treatment for many years. Our clinical study indicates that the treatment with QYHJ combined with chemotherapy has prolonged survival time of advanced pancreatic cancer patients [5, 6]. However, its underlying mechanism remains to be elucidated.

The transcription factor Nanog controls stemness acting as a key determinant of both embryonic stem cells self-renewal and differentiated somatic cells reprogramming to pluripotency. Nanog is a member of ANTP class NK family genes and plays a key role in stem cell self-renewal and pluripotency differentiation [7]. In addition to self-renewal regulation of embryonic development, the abnormal expression of Nanog gene is found in malignant germ cell tumors, such as embryonic carcinoma and seminoma [8]. The abnormal expression of Nanog is also detected in solid tumors, such as breast [9], gastrointestinal [10], and kidney [11] cancer. Here, we found that QYHJ treatment could downregulate the expression of Nanog. We assume that the expression of Nanog may be coordinated and downregulated by QYHJ in vitro and in vivo. Since aberrant Nanog expression occurs in tumorigenesis, therapeutics targeted...
Nanog may improve the outcomes of patients with pancreatic cancer, thus suggesting the use of QYHJ to further improve preventive and therapeutic approaches in patients with this devastating disease.

Thus, the aim of the study is to evaluate Nanog expression in human pancreatic cancer tissue and the effects of QYHJ on transcription factor Nanog in human pancreatic cancer stem cell.

2. Materials and Methods

2.1. Cell Lines and Reagents. Pancreatic cancer cell line PANC-1 was obtained from the Shanghai Cell Bank of the Chinese Academy of Sciences (Shanghai, China) and grown in complete growth medium as recommended by the manufacturer. CD24+/CD44+/ESA+ subpopulation cells were isolated from the pancreatic cancer cell lines PANC-1 as the previous description [12]. The cultured cells were maintained in a humidified 5% CO2 atmosphere at 37°C.

2.2. Drugs and Reagents. QYHJ formula, comprised of seven Chinese herb medicines (Hedyotidis herba, Amorphophallus konjac, herba scutellariae barbatae, Coix seed, akebia stem, fiveleaf gynostemma herb, and java amomum fruit), was prepared as previously described [13–15]. In short, QYHJ powder was obtained from Jiangyin Tianjiang Pharmaceutical Co., Ltd. To ensure standardization and maintain the interbatch reliability of QYHJ, a high performance liquid chromatography (HPLC) chromatographic fingerprint was developed for quality control. The fingerprint chromatograms of QYHJ formula are shown in our previous report [13–15]. The final decoction of QYHJ was prepared after dissolving the herbal powder in distilled water to the required concentration. The daily dosage for nude mice was 36 g/kg, once per day p.o., respectively, calculated according to the following human-mouse transfer formula: \( D_h = D_a \times \left( \frac{R_h}{R_a} \right) \times \left( \frac{W_a/W_h} {3} \right) \), where \( D_h \), \( D_a \), and \( W \) represent dosage, shape coefficient, and body weight, respectively, and \( a \) and \( b \) represent human and mouse, respectively. Gemcitabine (Eli Lilly) was dissolved in sterile PBS, 25 mg/kg [14, 15], twice per week by intraperitoneal injection. Antibodies of rabbit anti-human Nanog were purchased from Abcam. CCK-8 were purchased from Dojindo Molecular Technologies, Inc., and BD Matrigel™ Matrix basement membrane was purchased from BD Biosciences. Transwell insert (8 μm) was purchased from Corning Incorporated.

2.3. Cell Proliferation Assays. A total of \( 5 \times 10^3 \) cells were plated in duplicate wells of 96-well plates and allowed to adhere overnight. Cells were then treated with human recombinant QYHJ at concentrations ranging from 0 to 200 mg/mL. After 48 hours, indices of cell proliferation were determined with Cell Counting Kit-8 (Dojindo Molecular Technologies, Inc., Gaithersburg, MD).

2.4. Cell Cycle Analysis. For cell cycle analysis of cells, cells growing at low density (40%) in normal growth medium were treated with QYHJ (32 mg/mL) or vehicle. After 24 h, cells were fixed with 1% paraformaldehyde in PBS (phosphate-buffered saline) for 15 minutes and refixed with 70% ethanol. The cells were then treated following the standardized protocol, and cell cycle analyses were done by flow cytometry as described previously [12].

2.5. Cell Invasion and Migration Assays. Transwell chambers were coated with Matrigel for 3 h to form a basement membrane prior to use. Following treatment with QYHJ (32 mg/mL) for 24 h, the CD24+/CD44+/ESA+ PCSCs were harvested and seeded in the upper chamber at a density of 30,000 cells/well in 200 μL free-serum culture medium. Culture medium containing 10% FBS (600 μL) was added in the lower chamber as a chemoattractant. After incubation for 24 h at 37°C, all of the noninvaded cells were removed from the upper face of the membrane with a cotton swab. The invaded cells on the lower face of membrane were then fixed for 10 min with 4% paraformaldehyde (Genmed Sciences, Inc., Arlington, MA, USA) and stained with 0.2% crystal violet for 15 min. Cells that had invaded through the membrane were counted using the inverted microscope. The general procedure of the migration assay was similar to that of the invasion assay, with the exception that the membranes in each chamber were not coated with Matrigel and the number of cells seeded in the upper chamber was \( 5 \times 10^4 \) cells/well.

2.6. Colony Formation Assay. For colony formation, CD24+/CD44+/ESA+ PCSCs were seeded (500 cells/well) in six-well plates overnight. After 14 days, the culture medium was removed, and cells were briefly rinsed with PBS. The cells were then fixed with 4% paraformaldehyde and stained with 0.1% crystal violet, and colonies were counted by visual inspection.

2.7. RNA Extraction and Quantitative Real-Time PCR (qRT-PCR). Total RNA was extracted from frozen plasma or cultured cell lines using TRIzol reagent (Invitrogen, USA) according to the manufacturer’s instructions. With GAPDH as an internal control, qRT-PCR was performed for Nanog. Total RNA was then converted to cDNA by reverse transcription using oligo-dT primers and SuperScript II reverse transcriptase (Invitrogen). For qRT-PCR, three replicates of each sample were amplified in a 20 μL reaction mixture containing SYBR Green reaction mix (Qiagen, Germany) and 0.5 mM of primer and analyzed using a Roche Light-Cycler (Roche, Basel, Switzerland). The relative gene expression in cells was determined using the comparative delta-delta CT method \( (2^{-ΔΔC_t}) \). The fold change in gene expression of tissues was calculated using the standard ΔΔCT method. The primer sequences of Nanog are sense: 5’-GCAATGGTGTGACGCAGAAGGC-3’, antisense: 5’-TGGGTCTGGTTGCTCCAGGTTG-3’; GAPDH sense: 5’-GAATGGTTGACCGCAAGGCG-3’, antisense: 5’-GGATGTGACTATCCCAAGTTTGAAC-3’.

2.8. Western Blot Analysis. CD24+/CD44+/ESA+ PCSCs were washed in PBS and lysed with RIPA buffer (Invitrogen), and a bicinchoninic acid protein assay kit (Pierce, Rockford,
IL, USA) was used to calculate the protein concentration of each sample. Equivalent amounts of proteins were separated by SDS-PAGE and transferred to polyvinylidene fluoride membranes for immunoblotting. The membranes were blocked in 5% fat-free milk for 2 hours at room temperature, washed three times, then incubated with the following primary antibodies: rabbit anti-human Nanog antibody (1:200, lot: GRI54878-3, Santa Cruz Biotechnology, USA) and rabbit anti-human GAPDH antibody (1:1000, #ab18162, Abcam). GAPDH was used as a loading control. Horseradish peroxidase conjugated secondary antibodies (Cell Signaling Technology, Boston, USA) and an ECL chemiluminescence kit were used to detect bound antibody. Western blot was performed according to standard protocols [16].

2.9. In Vivo Xenograft Experiments. Female BALB/c-nu/nu nude mice, 4 to 6 weeks old, were obtained from Shanghai Laboratory Animal Center, Chinese Academy of Sciences (Shanghai, China), and housed in laminar flow cabinets under specific pathogen-free conditions with food and water ad libitum. The study protocol was approved by the Shanghai Medical Experimental Animal Care Committee. For QYHJ treatment, an appropriate concentration (36 g/kg) of QYHJ and gemcitabine 25 mg/kg, twice per week by i.p. injection, were fed to nude mice.

2.10. Immunohistochemical Analysis. Paraffin-embedded sections (4 μm) were stained with primary antibodies for Nanog (1:200) and then stained with HRP conjugated secondary antibodies. Sections were developed in diaminobenzidine and counterstained with hematoxylin. Images were taken, and five fields (200x) selected randomly from each section were examined. For the data quantification, integrated optical density (IOD) of positive expression was measured by Image Pro Plus 6.0 software.

2.11. Statistical Analysis. Kaplan-Meier analysis was used to evaluate OS, and log-rank test was used to compare OS between groups. The data were expressed as mean ± standard deviation. ANOVA and Student’s t-test were used to determine the statistical significance of differences between experimental groups, with p < 0.05 as the statistically significant level.

3. Results

3.1. Nanog Overexpression Is Associated with Clinicopathological Characteristics and Prognosis of Pancreatic Cancer Patients. To investigate the clinical relevance of the transcription factor Nanog in pancreatic cancer, we measured the expression levels of Nanog protein in 47 paraffin-embedded human PDAC samples by immunohistochemistry. As described in Section 2, the expression of Nanog was evaluated in terms of intensity and percentage separately and finally expressed as strong, moderate, weak, or absent. The representative images are shown in Figure 1 and the
TABLE I: Correlation of Nanog expression and clinicopathological characteristics in patients with pancreatic cancer.

| Parameters                        | Nanog IHC scores |
|-----------------------------------|-------------------|
|                                   | 3 (N = 12) | 2 (N = 15) | 1 (N = 11) | 0 (N = 9) | p value |
| Age                               |            |            |            |            |         |
| Mean (Range)                      | 57.5 (35–78)| 58.1 (52–76)| 56.9 (47–78)| 51.2 (39–75)| 53.3 (35–71)| 0.133*  |
| Gender                            |            |            |            |            |         |
| Male                              | 26         | 8          | 7          | 6          | 5        |
| Female                            | 21         | 4          | 8          | 5          | 4        | 0.491   |
| Tumor range                       |            |            |            |            |         |
| Confined                          | 26         | 5          | 12         | 7          | 2        |
| Invasion of adjacent organ        | 15         | 6          | 2          | 3          | 4        |
| Distal metastasis                 | 6          | 3          | 1          | 0          | 2        | 0.475   |
| Tumor size                        |            |            |            |            |         |
| ≤ 4 cm                            | 19         | 13         | 4          | 1          | 1        |
| > 4 cm                            | 28         | 12         | 8          | 5          | 3        | 0.041*  |
| Tumor location                    |            |            |            |            |         |
| Head                              | 34         | 18         | 7          | 8          | 2        |
| Body and tail                     | 13         | 6          | 4          | 2          | 1        | 0.832   |
| TNM stage                         |            |            |            |            |         |
| I and II                          | 38         | 14         | 7          | 9          | 9        |
| III and IV                        | 9          | 5          | 3          | 1          | 0        | <0.001* |
| Differentiation                   |            |            |            |            |         |
| Well and moderate                 | 35         | 12         | 5          | 11         | 7        |
| Poor                              | 12         | 8          | 2          | 1          | 1        | 0.012   |
| Liver metastasis                  |            |            |            |            |         |
| Yes                               | 24         | 8          | 9          | 4          | 3        |
| No                                | 23         | 5          | 4          | 5          | 9        | 0.037*  |
| CA19-9 (IU/mL)                    |            |            |            |            |         |
| ≤ 500                             | 9          | 2          | 3          | 1          | 3        |
| > 500                             | 36         |            |            |            | 0.067    |

All the other p values were calculated by Pearson Chi-square test. #: spearman rank correlation test. * denotes statistical significance.

IHC photo of Nanog from PanIN to PDAC was shown in Figure 2(b). We also analyzed the relationship between the intensity of Nanog staining and clinicopathological features. Statistical analysis confirmed that Nanog overexpression was correlated with tumor size, TNM stage, and liver metastasis (Table I). Furthermore, survival analysis displayed that higher Nanog staining intensity correlated with poorer prognosis in pancreatic cancer patients (log-rank test, p < 0.001, Figure 2(c)). Moreover, the univariate analysis revealed that large tumor size, advanced TNM stage, liver metastasis, and high Nanog expression were significantly associated with an increased risk of cancer-related death. The multivariate analysis demonstrated that, of note, high expression levels of Nanog were found to be significantly associated with poorer survival in patients (p < 0.001, Table 2). Meanwhile, the levels of Nanog in the plasma were detected between pancreatic cancer patients and health peoples, we found that lower plasma Nanog levels were significantly higher in patients with advanced pancreatic cancer, compared to the healthy group (Figure 2(a)).

3.2. QYHJ Treatment Can Reduce the Tumorigenicity of CD24+/CD44+/ESA+ PCSCs In Vivo. To examine the effect of the inhibition of QYHJ on the tumorigenic ability of PCSCs in vivo, CD24+/CD44+/ESA+ PCSCs were inoculated subcutaneously into nude mice. Both groups of nude mice were fed under the same conditions. Two weeks after injection, nude mice treated with saline had an obvious swelling at the injection site, whereas the nude mice treated with QYHJ did not demonstrate any swelling. 23 days after injection, all of the mice were sacrificed. Although the mice in both groups had varying sizes of subcutaneous tumors on their back, the results showed that subcutaneous tumors treated with QYHJ were significantly smaller in both size (p < 0.01, Figure 3(c))
and weight ($p < 0.01$, Figure 3(b)) than control group, which is treated with saline.

3.3. QYHJ Downregulates Nanog Expression in Tumor Samples. Although QYHJ effectiveness has been confirmed in a series of clinical trials [5, 6], the mechanisms by which it exerts its effects are not completely understood. To explore the changes in the protein levels of Nanog following treatment with QYHJ, we conducted immunohistochemical staining in tumor samples. Our results showed that the expression of Nanog and Ki-67 protein in the tumor tissues treated with QYHJ and GEM was reduced, whereas their expression in tumor tissues in control group was only weakly reduced or even enhanced (Figure 4). In summary, these experiments in vivo show that when PCSCs were treated with QYHJ and GEM, the tumorigenicity of these cells in nude mice is reduced and the expression of Nanog and Ki-67 is also downregulated. In summary, our results also showed that cotreatment with QYHJ and GEM significantly inhibited the expression of Nanog at protein level in vivo.

3.4. QYHJ Treatment Results in the Inhibition of In Vitro Proliferation and Invasion of PCSCs. Using a cell proliferation assay, we observed that the in vitro proliferation rate of PCSCs (from the PANC-1 cell lines) treated with QYHJ was significantly lower than control group ($p < 0.01$, Figure 5(a)). Next, we analyzed the proportion of cells in various stages of the cell cycle using flow cytometry, and the results indicate that QYHJ results in the blockage of PCSCs at the G2/M phase in the cell cycle and inhibits their proliferation ($p < 0.01$, Figure 5(b)). Further, the transwell invasion assay results showed that the number of cells invaded under the membrane in PCSCs treated with QYHJ was significantly less than those transfected with control ($p < 0.01$, Figure 5(d)).

At the same time, the soft agar colony formation assay results showed that the colony formation rate of PCSCs treated with QYHJ in soft agar was significantly lower than control group ($p < 0.01$, Figure 5(c)). These experiments show that treatment with QYHJ can effectively inhibit the in vitro proliferation and invasive ability of PCSCs.
Table 2: Univariate and multivariate analysis of prognostic factors influencing overall survival in 47 patients with pancreatic ductal adenocarcinoma undergoing surgery.

| Parameter                        | Univariate analysis | Multivariate analysis |
|----------------------------------|---------------------|-----------------------|
|                                  | HR                  | 95% CI                | p value | HR              | 95% CI            | p value |
| Age                              | 1.1                 | 0.5–2.4               | 0.53    |                 |                    |         |
| Gender                           |                     |                       |         |                 |                    |         |
| Male                             | 0.79                | 0.4–1.3               | 0.176   |                 |                    |         |
| Female                           |                     |                       |         |                 |                    |         |
| Tumor range                      |                     |                       |         |                 |                    |         |
| Confined                         |                     |                       |         |                 |                    |         |
| Invasion of adjacent organ       | 3.3                 | 1.65–7.21             |         |                 |                    |         |
| Distal metastasis                | 4.1                 | 2.65–10.69            | 0.61    |                 |                    |         |
| Tumor size                       |                     |                       |         |                 |                    |         |
| ≤4 cm                            | 2.1                 | 1.8–4.9               | 0.041*  | 1.3             | 0.57–3.77         | 0.19    |
| >4 cm                            |                     |                       |         |                 |                    |         |
| Tumor location                   |                     |                       |         |                 |                    |         |
| Head                             | 0.455               | 0.17–1.10             | 0.057   |                 |                    |         |
| Body and tail                    |                     |                       |         |                 |                    |         |
| TNM stage                        |                     |                       |         |                 |                    |         |
| I and II                         |                     |                       |         |                 |                    |         |
| III and IV                       | 4.0                 | 1.2–8.3               | <0.001* | 8.9             | 3.6–53.5          | 0.32    |
| Differentiation                  |                     |                       |         |                 |                    |         |
| Well and moderate                | 8.5                 | 4.3–76.9              | 0.55    |                 |                    |         |
| Poor                             |                     |                       |         |                 |                    |         |
| Liver metastasis                 |                     |                       |         |                 |                    |         |
| Yes                              | 5.8                 | 1.5–14.9              | 0.0013* | 6.6             | 0.89–14.2         | 0.062   |
| No                               |                     |                       |         |                 |                    |         |
| Nanog expression                 |                     |                       |         |                 |                    |         |
| Strong                           | 1.55                | 0.55–4.11             |         | 1.56            | 0.60–4.11         | <0.001* |
| Moderate                         | 3.0                 | 0.4–20.1              |         | 3.0             | 0.77–20.5         | 0.0013* |
| Weak                             | 7.65                | 5.21–32.3             | <0.001* | 8.10            | 4.22–25.0         | <0.01*  |
| Absent                           |                     |                       |         |                 |                    |         |

HR, hazard ratio; CI, confidence interval. * denotes statistical significance.

4. Discussion

Due to the poor prognosis, there is an urgent need to prolong pancreatic cancer patients’ lifetime. Previous studies have shown only limited benefit with current treatments. The prognosis of PDAC is extremely dismal and the disease is obviously resistant to current therapies [16]. Traditional Chinese medicine has had an advantage in cancer therapy for thousands of years. QYHJ has shown promising outcomes in treatment for patients with pancreatic cancer. In QYHJ treatment group, the survival rate of 5 years was 8.4%, and the median survival time was 7.6 months, obviously longer than that of control group [4]. QYHJ could benefit advanced pancreatic cancer patients by stabilizing tumors and prolonging life expectancy, with fewer side effects than those of chemotherapy or radiotherapy [5]. Another retrospective study also showed that, from January 2002 to December 2007, patients who took QYHJ based integrative treatment have much longer survival, 20 cases survive more than 3 years, of which 13 cases survive more than 5 years, and the longest survival time is 169 months [6]. These studies indicated that QYHJ might be a novel therapeutic option for pancreatic cancer treatment. Therefore, it is valuable to explore its antitumor mechanism.

Little is known about the clinical and biological function of transcription factor Nanog thus far. To our knowledge, the findings of our current study provide the first evidence of the potential clinical utility of Nanog expression as a prognostic factor in pancreatic carcinoma. Our current works indicate that Nanog overexpression correlates with TNM stage and prognosis of patients with pancreatic cancer. Strong evidences have suggested that overexpression of Nanog is closely related to tumorigenesis, tumor metastasis, and distant recurrence after chemoradiotherapy [17, 18]. Nanog was found to be upregulated, which enhanced the expression of typical cancer stem cell markers, such as CD44, CD133, and ALDH1A1 in prostate cancer [19]. However, the role of transcription factor Nanog in pancreatic cancer stem cells is still elusive.
Figure 3: QYHJ treatment can reduce the tumorigenicity of PCSCs in nude mice. ∗ indicates $p$ value < 0.05 and ∗∗ indicates $p$ value < 0.01.

Figure 4: Immunohistochemistry analyses on expression of Nanog/Ki-67 after QYHJ and GEM treatment in pancreatic tumor tissues (scale bar, 100 μm).
Figure 5: QYHJ treatment can effectively inhibit the *in vitro* proliferation, invasion, and cell cycle progression of pancreatic cancer stem cells. ** indicates *p* value < 0.01.
In a previous study, we demonstrated that QYHJ exerted an inhibitory effect on the growth of human pancreatic cancer cell and liver metastasis, perhaps by targeting VEGF and Cyr61 [20]. However, the mechanisms leading to growth arrest remain unclear. In the current study, we observed that QYHJ downregulated Nanog expression in cancer stem cells at a transcriptional level as well as promoted degradation. We also evaluated Nanog protein expression in human pancreatic cancer tissue by immunohistochemistry. We found that Nanog is upregulated in human pancreatic cancer tissues compared to normal adjacent pancreatic tissues. These results indicate that overexpression of Nanog may play a key role in the development or the progression of pancreatic cancer.

In conclusion, we found that Nanog is overexpressed in pancreatic cancer tissues and its expression is downregulated in vitro and in vivo by QYHJ. QYHJ inhibited the proliferation and invasion of human pancreatic cancer stem cell PANC-1, partly through downregulation of transcription factor Nanog expression. Nanog acts as a therapeutic target of QYHJ in the treatment of pancreatic cancer stem cells, and its expression status mediates different responses to QYHJ treatment of pancreatic cancer stem cells.

Competing Interests
There is no conflict of interests regarding the publication of this paper.

Authors’ Contributions
Song Gao and Yan Pan contributed equally to this work.

Acknowledgments
The authors would like to thank Professor Hao Xi from Shanghai Tenth People’s Hospital, Shanghai, for providing pancreatic cancer samples. They would like to sincerely thank Lao I. Weng and Lei Dong from Department of Pathology, Shanghai Cancer Center, for helping to evaluate the histological scores. This study was supported by the grants from National Natural Science Foundation of China (no. 81373894) and Development Project of Shanghai Peak Disciplines-Integrated Chinese and Western Medicine.

References
[1] C. L. Wolfgang, J. M. Herman, D. A. Laheru et al., “Recent progress in pancreatic cancer,” CA: A Cancer Journal for Clinicians, vol. 63, no. 5, pp. 318–348, 2013.
[2] A. Vincent, J. Herman, R. Schulick, R. H. Hruban, and M. Goggins, “Pancreatic cancer,” The Lancet, vol. 378, no. 9791, pp. 607–620, 2011.
[3] R. Gutt, S. L. Liauw, and R. R. Weichselbaum, “The role of radiotherapy in locally advanced pancreatic carcinoma,” Nature Reviews Gastroenterology & Hepatology, vol. 7, no. 8, pp. 437–447, 2010.
[4] R. Siegel, D. Naishadham, and A. Jemal, “Cancer statistics, 2013,” CA: Cancer Journal for Clinicians, vol. 63, no. 1, pp. II–30, 2013.
[5] Y. H. Shen, L. M. Liu, X. Y. Zhu et al., “A clinical trial on the effect of Qingyi Huaji herbal decoction combined with transcatherter arterial chemotherapy and radiotherapy for inoperable pancreatic cancer,” Journal of Traditional Chinese Medicine, vol. 51, no. 12, pp. 1093–1096, 2010.
[6] Y. L. Xu, S. Gao, L. M. Liu et al., “Clinical analysis on 20 cases of long term survival patients with advanced pancreatic cancer,” China Journal of Traditional Chinese Medicine and Pharmacy, vol. 29, no. 8, pp. 2679–2681, 2014.
[7] I. Chambers, D. Colby, M. Robertson et al., “Functional expression cloning of Nanog, a pluripotency sustaining factor in embryonic stem cells,” Cell, vol. 113, no. 5, pp. 643–655, 2003.
[8] C. E. Høei-Hansen, “Application of stem cell markers in search for neoplastic germ cells in dysgenetic gonads, extragonadal tumours, and in semen of infertile men,” Cancer Treatment Reviews, vol. 34, no. 4, pp. 348–367, 2008.
[9] U. I. Ezeh, P. J. Turek, R. A. Reijo Pera, and A. T. Clark, “Human embryonic stem cell genes OCT4, NANOG, STELLAR, and GDF3 are expressed in both seminoma and breast carcinoma,” Cancer, vol. 104, no. 10, pp. 2255–2265, 2005.
[10] N. Miyoshi, H. Ishii, K.-I. Nagai et al., “Defined factors induce reprogramming of gastrointestinal cancer cells,” Proceedings of the National Academy of Sciences of the United States of America, vol. 107, no. 1, pp. 40–45, 2010.
[11] B. Bussolati, S. Bruno, C. Grange, U. Ferrando, and G. Camussi, “Identification of a tumor-initiating stem cell population in human renal carcinomas,” The FASEB Journal, vol. 22, no. 10, pp. 3696–3705, 2008.
[12] S. Gao, P. Wang, Y. Hua et al., “ROr functions as a ceRNA to regulate Nanog expression by sponging miR-145 and predicts poor prognosis in pancreatic cancer,” Oncotarget, vol. 7, no. 2, pp. 1608–1618, 2016.
[13] Z. Chen, L.-Y. Chen, P. Wang, H.-Y. Dai, S. Gao, and K. Wang, “Tumor microenvironment varies under different TCM ZHENG models and correlates with treatment response to herbal medicine,” Evidence-Based Complementary and Alternative Medicine, vol. 2012, Article ID 635702, 10 pages, 2012.
[14] P. Wang, Z. Chen, Z.-Q. Meng et al., “Ski acts as therapeutic target of Qingyi huajiu formula in the treatment of SW1990 pancreatic cancer,” Integrative Cancer Therapies, vol. 9, no. 1, pp. 50–58, 2010.
[15] J. Zhang, P. Wang, H. Ouyang et al., “Targeting cancer-related inflammation: Chinese Herbal Medicine Inhibits Epithelial-to-Mesenchymal Transition in Pancreatic Cancer,” PLoS ONE, vol. 8, no. 7, article e70334, 2013.
[16] D. Li, K. Xie, R. Wolf, and J. L. Abbruzzese, “Pancreatic cancer,” The Lancet, vol. 363, no. 9414, pp. 1049–1057, 2004.
[17] I. Ben-Porath, M. W. Thomson, V. J. Carey et al., “An embryonic stem cell–like gene expression signature in poorly differentiated aggressive human tumors,” Nature Genetics, vol. 40, no. 5, pp. 499–507, 2008.
[18] S. Feske, “Calcium signalling in lymphocyte activation and disease,” Nature Reviews Immunology, vol. 7, no. 9, pp. 690–702, 2007.
[19] C. R. Jeter, B. Liu, X. Liu et al., “NANOG promotes cancer stem cell characteristics and prostate cancer resistance to androgen deprivation,” Oncogene, vol. 30, no. 36, pp. 3833–3845, 2011.
[20] J.-H. Yin, W.-D. Shi, X.-Y. Zhu, Z. Chen, and L.-M. Liu, “Qingyi Huajiu formula inhibits progress of liver metastases from advanced pancreatic cancer xenograft by targeting to decrease expression of Cyr61 and VEGF,” Integrative Cancer Therapies, vol. 11, no. 1, pp. 37–47, 2012.